# SYNGENE (SYNGENE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/syngene

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹368.05
- Change: -3.20%
- As of: 2026-09-18
- 1D return: -2.93%
- 5D return: -3.89%
- 1M return: -6.69%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 17, 2026, Syngene's stock is trading at ₹380.2, indicating a bearish trend on the daily timeframe. The daily chart shows the price below key moving averages including the 20-day EMA (₹392.07) and 50-day SMA (₹403.07), with a bearish Supertrend signal at ₹403.6. This is supported by a declining ADX value of 21.47, suggesting weakening trend strength, and negative DI readings relative to positive DI (25.28 vs 11.33). The weekly timeframe also shows a bearish Supertrend at ₹454.22, with the price below the 20-day EMA (₹417.89) and 50-day SMA (₹483.89). In contrast, the monthly timeframe exhibits a bullish Supertrend at ₹375.57, with the price above this level, although the 20-day EMA (₹525.47) and 20-day SMA (₹550.59) are significantly higher, indicating a strong monthly uptrend that is currently being challenged on shorter timeframes. Recent daily patterns include an active "Doji" and "Inside Bar" on September 17, 2026, suggesting potential indecision. The stock is currently trading near its nearest support level of ₹378.9, which is approximately 0.34% below the current price. The nearest resistance is at ₹383.6, about 0.89% higher. The stock has experienced a drawdown of -0.57% and has an annualized volatility of 0.31. Key watch conditions include monitoring the price action around the ₹378.9 support and ₹383.6 resistance levels. A break below ₹378.9 could signal further downside, while a sustained move above ₹383.6 may indicate a short-term recovery. The divergence between the daily/weekly bearish signals and the monthly bullish Supertrend warrants close observation for potential trend alignment or continuation of the short-term weakness within a larger monthly uptrend.

- The stock closed at ₹380.2 on September 17, 2026, with daily and weekly timeframes showing bearish signals.
- Nearest support is observed at ₹378.9 (0.34% below current price), and nearest resistance is at ₹383.6 (0.89% above current price).
- Daily trend indicators show the price below key moving averages (20-day EMA ₹392.07, 50-day SMA ₹403.07) and a bearish Supertrend at ₹403.6.
- Monthly timeframe shows a bullish Supertrend at ₹375.57, contrasting with shorter-term bearish indicators.
- Watch for price action around ₹378.9 support and ₹383.6 resistance for potential trend confirmation or reversal cues.

- Bearish Engulfing Reversal
- Doji
- Inside Bar
- Evening Star
- Outside Bar

### News Context

Syngene International Limited has announced its participation in an upcoming investor meet organized by Kotak Group. The company is scheduled for a physical one-on-one meeting with Healthcare Forum 2026 in Mumbai on September 17, 2026. Syngene has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during this event. This follows a series of filings on September 11 and September 12, 2026, confirming the schedule for this and other analyst or institutional investor meetings. Earlier in the month, on September 1, 2026, Syngene informed the exchange about the grant of 14,26,061 Performance Share Units (PSUs) under its Long Term Incentive Performance Share Plan (PSP) 2023 to eligible employees. These PSUs have an exercise price of ₹10 per unit and are subject to a three-year vesting period, with options exercisable within five years from vesting.

- Syngene International Limited confirmed participation in a Healthcare Forum 2026 investor meeting organized by Kotak Group on September 17, 2026, in Mumbai.
- The company stated that no Unpublished Price Sensitive Information (UPSI) would be shared during the investor meeting.
- On September 1, 2026, Syngene granted 14,26,061 Performance Share Units (PSUs) under its PSP 2023 plan to employees.
- The PSUs have an exercise price of ₹10 and a three-year cliff vesting schedule.

- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange regarding Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 (Plan). |SUBJECT: Updates

### What Changed

Syngene International, trading on the NSE, has experienced a minor price fluctuation. As of September 17, 2026, the stock closed at ₹380.2, a slight increase from its previous close of ₹380.1 on the same day. There are no new filings or news developments reported as of September 18, 2026, indicating that the company's operational and strategic context remains unchanged from earlier periods. The technical indicators for daily and weekly trends are not available for comparison.

- Stock closed at ₹380.2 on September 17, 2026, compared to ₹380.1 on the same day.
- No new filings or news were reported as of September 18, 2026.
- Daily and weekly trend data were not available for comparison.

### Official Filings

Syngene International Limited has been actively engaging with investors and analysts. The company participated in a physical one-on-one meeting with Healthcare Forum 2026, organized by Kotak Group, on September 17, 2026. Prior to this, Syngene attended a group meeting with Goldman Sachs at the Goldman Sachs Asia Leaders Conference 2026 in Hong Kong on August 31, 2026, and a virtual one-on-one meeting with Entrust Family Office on August 28, 2026. Earlier in August, the company participated in the Emkay Confluence 2026 conference in Mumbai on August 13-14, 2026. In all these instances, the company explicitly stated that no Unpublished Price Sensitive Information (UPSI) would be disclosed. On a separate note, on September 1, 2026, Syngene granted 14,26,061 Performance Share Units (PSUs) under its Long Term Incentive Performance Share Plan (PSP) 2023. These PSUs have an exercise price of ₹10 per unit and vest 100% after a three-year performance period, with options exercisable within five years of vesting. Additionally, on July 29, 2026, shareholders approved resolutions at the 33rd Annual General Meeting, including the adoption of financial statements for the year ended March 31, 2026, and a final dividend of ₹1.25 per equity share.

- Syngene International Limited participated in investor meetings with Healthcare Forum 2026 (September 17, 2026), Goldman Sachs Asia Leaders Conference 2026 (August 31, 2026), Entrust Family Office (August 28, 2026), and Emkay Confluence 2026 (August 13-14, 2026), confirming no UPSI would be disclosed.
- On September 1, 2026, 14,26,061 Performance Share Units (PSUs) were granted under the PSP 2023, with an exercise price of ₹10 per unit and a three-year vesting period.
- Shareholders approved a final dividend of ₹1.25 per equity share at the 33rd Annual General Meeting held on July 29, 2026.
- The financial statements for the year ended March 31, 2026, were adopted at the Annual General Meeting on July 29, 2026.
- Key appointments, including Mr. Siddharth Mittal as MD & CEO and new directors, were approved at the Annual General Meeting on July 29, 2026.

- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange regarding Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 (Plan). |SUBJECT: Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Syngene International's recent operating performance shows a mixed trajectory across the reported periods. Revenue from operations saw an increase from ₹917.10 crore in Q3 FY2025-26 to ₹1,036.50 crore in Q4 FY2025-26, before declining to ₹736 crore in Q1 FY2026-27. Expenses followed a similar pattern, rising from ₹833.50 crore in Q3 FY2025-26 to ₹856.70 crore in Q4 FY2025-26, and then decreasing to ₹767 crore in Q1 FY2026-27.

Profitability metrics indicate a significant shift. Profit Before Exceptional Items And Tax was ₹99 crore in Q3 FY2025-26, surged to ₹202 crore in Q4 FY2025-26, but turned negative at -₹5.70 crore in Q1 FY2026-27. This decline in operating profit, coupled with exceptional items before tax of -₹13.50 crore in Q1 FY2026-27, resulted in a Profit Before Tax of -₹19.20 crore for the latest quarter, compared to ₹196 crore in Q4 FY2025-26 and ₹28.40 crore in Q3 FY2025-26. Finance costs remained relatively stable, ranging from ₹9.60 crore to ₹12.10 crore across these periods.

Key monitoring areas for investors include the reversal of the recent decline in revenue and the return to profitability. Understanding the drivers behind the negative Profit Before Tax in Q1 FY2026-27, particularly the impact of exceptional items, will be crucial.

- Revenue from operations was ₹917.10 crore in Q3 FY2025-26, ₹1,036.50 crore in Q4 FY2025-26, and ₹736 crore in Q1 FY2026-27.
- Profit Before Tax was ₹28.40 crore in Q3 FY2025-26, ₹196 crore in Q4 FY2025-26, and -₹19.20 crore in Q1 FY2026-27.
- Exceptional Items Before Tax were -₹70.60 crore in Q3 FY2025-26, -₹6 crore in Q4 FY2025-26, and -₹13.50 crore in Q1 FY2026-27.
- Finance Costs ranged from ₹9.60 crore to ₹12.10 crore across the reported quarters.

### Bull Case

The company's monthly trend indicators show a bullish Supertrend signal as of the last observed date, suggesting potential upward momentum over a longer timeframe. However, daily and weekly trend indicators are currently bearish, with Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs) indicating downward price slopes. The stock is trading below its 20-day, 50-day, and 200-day SMAs and EMAs on a daily basis, and below its 20-day and 50-day SMAs and EMAs on a weekly basis. Several support levels are identified between ₹370.7 and ₹378.9, while resistance is noted around ₹383.6 and higher.

- Monthly Supertrend indicator is bullish.
- Daily and weekly trend indicators are bearish.
- Current price is below key daily and weekly moving averages.
- Nearest support levels are between ₹370.7 and ₹378.9.

### Bear Case

The company's stock is exhibiting a bearish trend on a daily and weekly basis, with key moving averages like the 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs) trading above the current closing price of ₹380.2. The daily Supertrend indicator is also signaling a bearish direction. This technical setup suggests a prevailing downward momentum in the short to medium term. Furthermore, the stock has experienced significant drawdowns, with a current drawdown of -0.57 and a maximum drawdown of -0.57, indicating substantial price depreciation from its peak. The year-to-date return is -0.42, and the one-year return is also -0.42, highlighting a prolonged period of underperformance.

- Daily Supertrend indicator is bearish as of 2026-09-17.
- Weekly Supertrend indicator is bearish as of 2026-09-17.
- The stock's year-to-date return was -0.42 as of the latest reporting period.
- The stock's one-year return was -0.42 as of the latest reporting period.
- The maximum drawdown observed is -0.57.

### FAQs

**What recent corporate actions has Syngene International Limited undertaken regarding employee incentives?**

On September 1, 2026, Syngene International Limited granted 14,26,061 Performance Share Units (PSUs) to eligible employees under its Long Term Incentive Performance Share Plan (PSP) 2023. These PSUs have an exercise price of ₹10 per unit and are subject to a three-year vesting period. Upon vesting, each PSU can be exercised for one equity share within five years, subject to payment of the exercise price and applicable taxes.

**What is the recent technical trend for Syngene International Limited's stock?**

As of September 17, 2026, the daily trend for Syngene International Limited's stock indicates a bearish sentiment, with the Supertrend indicator at 403.6 and a bearish direction. The closing price was ₹380.2, below the 20-day Exponential Moving Average (EMA) of ₹392.07 and the 50-day EMA of ₹404.05. The weekly trend also shows a bearish Supertrend direction at 454.22, with the closing price below both the 20-day EMA (₹417.89) and 50-day EMA (₹483.89). However, the monthly trend shows a bullish Supertrend direction at ₹375.57, though the closing price of ₹380.2 is below the 20-day EMA of ₹525.47.

**What are the key support and resistance levels for Syngene International Limited's stock?**

As of September 17, 2026, key support levels for Syngene International Limited's stock are identified at ₹378.9 (0.34% below current price), ₹377.62 (0.68% below), ₹375.4 (1.26% below), and ₹370.7 (2.5% below). Resistance levels are noted at ₹383.6 (0.89% above current price), ₹387.1 (1.81% above), ₹391.8 (3.05% above), and ₹448.65 (18.0% above).

**What investor engagement activities has Syngene International Limited scheduled?**

Syngene International Limited has scheduled a physical one-on-one meeting with Healthcare Forum 2026, organized by Kotak Group, in Mumbai on September 17, 2026. The company has also indicated other analyst and institutional investor meetings. Syngene International Limited has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these events.

- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Syngene International Limited has informed the Exchange regarding Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 (Plan). |SUBJECT: Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Downtrend
- Weekly trend: Moderate Downtrend
- Pivot point: ₹379.27
- Risk regime: Higher Price Risk

### Resistance levels
- 448.65
- 463.8
- 490.7

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -2.93% |
| return_10 | -7.92% |
| return_1m | -8.67% |
| return_1y | -43.91% |
| return_20 | -6.69% |
| return_3m | -16.18% |
| return_5 | -3.89% |
| return_6m | -12.10% |
| return_since_start | -58.03% |
| return_ytd | -43.24% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -58.03% |
| annualized_volatility | +31.03% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Sharp Revenue Decline Leads to First Quarterly Loss

Syngene International reported a steep drop in revenue for the first quarter of FY2026-27, ending on 30 June 2026. The fall in sales occurred alongside a slower reduction in costs, pushing the company into its first net loss in the recent reporting sequence. The revenue contraction was the central factor behind the result.

## Revenue Decline

Revenue from operations was ₹736 crore for the quarter, a decrease of ₹300.5 crore or 28.99% from the ₹1,036.5 crore reported in the prior quarter. Compared to the same quarter a year earlier, revenue fell by ₹138.5 crore or 15.84%, dropping below the ₹874.5 crore recorded in the year-ago period. This contraction breaks the sequential growth pattern observed across the four quarters of the previous fiscal year, during which revenue steadily increased from ₹874.5 crore to ₹1,036.5 crore.

## Profitability and Cost Structure

Total expenses for the quarter were ₹767 crore, a decrease of ₹89.7 crore or 10.47% from the prior quarter and ₹23.9 crore or 3.02% from the year-ago quarter. Because expenses fell more slowly than revenue, the company recorded a loss before exceptional items and tax of ₹5.7 crore. This represents a swing of ₹207.7 crore from the prior quarter’s profit of ₹202 crore and ₹107 crore from the year-ago quarter’s profit of ₹101.3 crore.

## Exceptional Items and Tax

The company reported exceptional charges of ₹13.5 crore, though this figure is subject to confirmation, compared to ₹6 crore in the prior quarter and none in the year-ago quarter. Following these charges, profit before tax fell to a loss of ₹19.2 crore, down from a profit of ₹196 crore in the prior quarter and ₹101.3 crore a year earlier. A tax credit of ₹10.2 crore reduced the loss further, resulting in a net loss of ₹9 crore. Basic earnings per share was ₹-0.22, compared to ₹3.68 in the prior quarter and ₹2.16 a year ago.

## Other Comprehensive Income

Other comprehensive income was ₹35.3 crore, a notable improvement from a loss of ₹85.7 crore in the prior quarter and an increase from ₹21.4 crore a year earlier. This gain partially offset the net loss, bringing total comprehensive income to ₹26.3 crore for the quarter.

## Key Takeaway

The quarter was driven by a sharp revenue decline that outpaced expense reductions, pushing the company into a net loss. Reported exceptional charges added to the deficit, while a tax credit and a gain in other comprehensive income limited the overall loss. The result marks a shift from consecutive profitable quarters to a loss-making period, with the revenue contraction serving as the main factor.

### Ratios

## Official filings

- 2026-09-12 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_12092026202117_Investorcallintimation17September2026.pdf)
- 2026-09-12 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20260912_202914365.xml)
- 2026-09-11 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_11092026191209_Investorcallintimation17September2026.pdf)
- 2026-09-11 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20260911_192350204.xml)
- 2026-09-01 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_01092026232040_GrantofPSUs_01092026.pdf)
- 2026-08-25 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20260825_164002522.xml)
- 2026-08-24 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_24082026144009_Investorcallintimation28082026.pdf)
- 2026-08-10 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_10082026170952_Investorcallintimation13-14082026.pdf)
- 2026-08-06 — Generic Announcement: Syngene International Limited has provided a web link to the transcript of its Q1 FY2027 Earnings Conference call, which was held on July 30, 2026. This intimation is in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_06082026183626_transcriptinvestorcallJuly2026.pdf)
- 2026-07-31 — Generic Announcement: Syngene International Limited's 33rd Annual General Meeting, held on July 29, 2026, saw shareholders approve resolutions 1 through 9. These resolutions included adopting the financial statements for the year ended March 31, 2026, declaring a final dividend of Rs. 1.25 per equity share, and approving the appointments of Professor Catherine Rosenberg, Mr. Siddharth Mittal as MD & CEO, Dr. Vijaya Chandru, Dr. Arun Chandavarkar, and Ms. Vinita Bali to directorial positions. The appointment of M/s. S. R. Batliboi & Associates LLP as statutory auditors was also approved. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_31072026141754_SEIntimationVRSRAGM_Signed.pdf)
- 2026-07-30 — Official Filing: Syngene International Limited has disclosed an audio recording of a call held on July 30, 2026, which concluded at 09:00:00. The recording was uploaded to the company's website on July 30, 2026, at 14:30:00, and is available at syngeneintl.com/wp-content/uploads/2026/07/audio-2026.mp3. Prior intimation of this earnings call was provided to the exchange on July 22, 2026.
- 2026-07-30 — Generic Announcement: Syngene International Limited has provided an intimation regarding the audio recording of its Q1 FY27 Earnings Call, conducted on July 30, 2026. The recording has been uploaded to the company's website and is available via a provided link, in compliance with SEBI Listing Regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_30072026174929_audioRecordingcoveringletter.pdf)
- 2026-07-30 — Generic Announcement: Syngene International Limited published its unaudited consolidated financial results for the quarter ended June 30, 2026, in the Financial Express and Vijayavani newspapers on July 30, 2026. The results, approved by the Board of Directors on July 29, 2026, show revenue from operations of Rs. 7,360 million and a net profit after tax of Rs. (90) million for the quarter. The company also reported total comprehensive income attributable to shareholders of Rs. 263 million for the period. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_30072026174651_SEIntimationNewsAd_.pdf)
- 2026-07-29 — Generic Announcement: Syngene International Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 29, 2026. The company also reported the voluntary liquidation of its subsidiary, Syngene Manufacturing Limited, which commenced on June 15, 2026. Additionally, the Board recommended a final dividend of Rs. 1.25 per equity share. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29072026173251_OutcomeQ1_Signed.pdf)
- 2026-07-29 — Earnings Presentation: Syngene International Limited has released its investor presentation for the quarter ended June 30, 2026. The company reported Revenue from Operations of Rs 736 Cr, a 16% year-over-year decrease, and an Operating EBITDA margin of 12%, down from 24% in Q1 FY26. This performance was impacted by reduced offtake from a major client and forex losses, partially offset by cost optimization. Siddharth Mittal assumed the role of Managing Director & CEO on July 1, 2026. Syngene also signed an MoU with THSTI for clinical development and bioanalytical sciences and enhanced its AI-enabled scientific platform. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29072026211514_SEIntimationIP.pdf)
- 2026-07-29 — Press Release: Syngene International Limited reported Q1 FY27 revenue from operations of Rs. 736 Cr and Operating EBITDA of Rs. 91 Cr, a year-over-year decrease of 16% and 56% respectively. The company experienced a significant impact from the lack of offtake from a major biologics client and a forex hedge loss. Kiran Mazumdar-Shaw has taken on the role of Executive Chairperson to focus on CDMO and AI-led services, while Siddharth Mittal assumes the CEO position. Syngene also announced an MoU with BRIC-THSTI for clinical development and strengthened its AI platform, Syn.AI. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29072026180827_PRJuly292026.pdf)
- 2026-07-29 — Generic Announcement: Syngene International Limited held its 33rd Annual General Meeting on July 29, 2026, via video conference. The meeting transacted nine resolutions, including the adoption of audited financial statements for the year ended March 31, 2026, and the declaration of a final dividend of Rs. 1.25 per equity share. Key appointments and approvals included the appointment of S.R. Batliboi & Associates LLP as statutory auditors and the approval of remuneration for directors and the Managing Director and CEO, Siddharth Mittal. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29072026205626_OutcomeofAGM_Signed.pdf)
- 2026-07-29 — Official Filing: Syngene International Limited reported the resignation of Mr. Kush Parmar as a Non-Executive Independent Director, effective July 29, 2026. The resignation is due to existing and increasing commitments in the USA, preventing sufficient time devotion to the company while residing abroad. The company confirmed no other material reasons for the resignation.
- 2026-07-29 — Management Change: Syngene International Limited announced the resignation of Independent Director Mr. Kush Parmar, effective July 29, 2026, due to existing and increasing commitments in the USA and inability to devote sufficient time while residing outside India. Mr. Parmar will also cease to be a member of the Risk Management Committee and the Science and Technology Committee. He confirmed no other material reasons for his resignation. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29072026200047_SEIntimationKush.pdf)
- 2026-07-28 — Official Filing: Syngene International Limited will hold an Earning/Quarterly Call on July 30, 2026, at 09:00 AM IST to discuss its Q1 FY 2027 results. The virtual group meeting will take place in Bengaluru. Further details and registration can be accessed via the provided weblink.
- 2026-07-22 — Generic Announcement: Syngene International Limited will hold a conference call for analysts and investors on July 30, 2026, at 9:00 AM IST to discuss its financial results for the quarter ended June 2026. The call will include a management discussion and a Q&A session. A replay facility will be available from July 30, 2026, to August 5, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_22072026180353_investorcallinitimation_July30072026.pdf)
- 2026-07-14 — Generic Announcement: Syngene International Limited announced that Mr. Surender Sharma, General Counsel and a member of the Executive Committee, will be leaving the company by mutual consent effective July 15, 2026. This change is disclosed under Regulation 30 of the SEBI Listing Regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_14072026174809_SEDisclosure_July152026.pdf)
- 2026-07-10 — Generic Announcement: Syngene International Limited has furnished details of securities dematerialized during the quarter ended June 30, 2026, to all stock exchanges where its shares are listed, as required by SEBI regulations. KFin Technologies Limited, the Registrar and Transfer Agent, confirmed this action on July 3, 2026, stating that dematerialization requests were processed within 15 days of receipt for the period of April 1, 2026, to June 30, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_10072026180953_SEIntimationReg74_5_.pdf)
- 2026-07-08 — Official Filing: B S R & Co. LLP resigned as the Statutory Auditor of Syngene Scientific Solutions Limited, a material subsidiary of Syngene International Limited, effective July 7, 2026. The resignation is due to the management's intention to align auditors with the holding company, Syngene International Limited, because of mandatory firm rotation under the Companies Act, 2013. B S R & Co. LLP was appointed on July 21, 2023, and their term was scheduled to expire at the conclusion of the 6th Annual General Meeting after the financial year ended March 31, 2028. The auditor's latest submission prior to resignation was an Audit Report dated April 28, 2026.
- 2026-07-08 — Management Change: Syngene Scientific Solutions Limited, a material subsidiary of Syngene International Limited, has accepted the resignation of its statutory auditors, B S R & Co. LLP, effective July 7, 2026. The auditors cited the need to align with the holding company's auditors due to mandatory rotation requirements under the Companies Act, 2013, as the reason for their resignation. B S R & Co. LLP had completed their audit for the period ending March 31, 2026, and issued their report on April 28, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_08072026184107_SEIntimationStatAuditorSSSL.pdf)

## News and market events

- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-13 — MONEYCONTROL: **Kenneth Andrade-backed Old Bridge MF adds Jubilant FoodWorks, Redington, Delhivery; exits Axis Bank, Syngene International** — Old Bridge MF, Kenneth Andrade — [Source](https://www.moneycontrol.com/news/business/markets/kenneth-andrade-backed-old-bridge-mf-adds-jubilant-foodworks-redington-delhivery-exits-axis-bank-syngene-international-14004150.html)
- 2026-07-30 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty back above 24,250; KPIT Tech shares decline over 7%** — Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside will be key for the Nifty, while the July 17 high of 24,367 will be the first hurdle to cross on the upside. The Nifty Bank has taken a backseat after the IT outperformance, but it remains to be seen whether IT could hold fort for another day today. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-expiry-infosys-it-eicher-dabur-vedanta-irfc-asian-paints-share-price-liveblog-19957305.htm)
- 2026-07-30 — CNBC-TV18: **The biggest movers on the Nifty 500 index today** — From strong Q1 earnings beats to margin pressures, here's a complete look at what drove today's biggest Nifty 500 movers and how each stock stacks up against its 52-week levels. Check out which stocks were moving the Nifty 500 at market open today. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-redington-balkrishna-syrma-gallant-wipro-hexaware-syngene-waaree-19957530.htm)
- 2026-07-30 — CNBC-TV18: **Syngene shares down 8% after Q1 results disappointment, revenue outlook cut** — Management expects the first half of FY27 to remain challenging, with Syngene's revenue likely to decline during the period. However, it anticipates business momentum to improve in the second half, which should partly offset the weak first-half performance. — [Source](https://www.cnbctv18.com/market/syngene-shares-in-focus-after-q1-results-disappointment-revenue-outlook-cut-19957401.htm)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: Eicher Motors target price raised; MTAR Tech up 5%, M&M reports today** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)

## Business profile

**Strategic vision:** Integrated scientific services for drug discovery and development.

### Business segments
- **Discovery Services:** These services span early-stage research from target identification to the delivery of drug candidates for further development, employing a target-focused, modality- and therapeutic area-agnostic approach.
- **Development Services:** Syngene offers robust and scalable Chemical Development services, involving route scouting for complex APIs, method development, and cGMP manufacturing.
- **Manufacturing Services:** Syngene undertakes cGMP manufacturing for both small molecules and biologics, providing solutions from GLP-Tox batches to clinical supplies, scale-up, launch, and commercial manufacturing.

### Competitive strengths
- Offers integrated scientific services across the entire drug discovery and development value chain.
- Provides customized end-to-end solutions for R&D and manufacturing requirements.
- Focuses on collaborative partnerships and integrated collaborations.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/syngene
Markdown representation: https://faxioms.com/stocks/syngene?render=md